Home
Immediapress
Pr Newswire
Comunicato stampa - contenuto promozionale
Responsabilità editoriale PrNewswire
Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
SUZHOU, China and MÖLNDAL, Sweden, May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together 'Ribo') announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a
308 words~1 min read
